Nyxoah (NYXH) secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.
The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.
Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.